Inogen, Inc. (INGN)

In the past six months, Inogen's stock experienced several notable events. In Q1 2026, Inogen reported revenue of $85.1 million, a 3.4% increase year-over-year, driven by international demand for portable oxygen concentrators. The company authorized a $30.0 million share repurchase program, repurchasing approximately 298,100 shares for nearly $1.9 million in Q1 2026. Inogen introduced Aurora CPAP masks in the U.S. and launched the Rove 6 portable oxygen concentrator in Brazil. As of April 22, 2026, Inogen's shares had gained 3.6% year-to-date, but as of July 17, 2025, a 13% pullback added to one-year losses for institutional owners.

Inogen, Inc. experiences demand seasonality for its products and services, with the second and third quarters historically being the strongest for profitability.

Inogen, Inc. is a global medical technology company focused on respiratory health products for homecare, operating in the Healthcare sector, specifically in Healthcare Equipment & Supplies and Medical Devices. The company's core products include Inogen One and Rove systems for ambulatory oxygen therapy, the Inogen Voxi 5 stationary oxygen concentrator, Aurora CPAP masks for the sleep apnea market, and Simeox for airway clearance. The company also offers related accessories and rents its products directly to patients.

Inogen, Inc. operates in the United States and internationally, with international sales contributing significantly to revenue. The company is expanding its global reach into Eastern Europe, Latin America, and the Asia Pacific region. In 2024, international B2B sales accounted for 34.9% of total revenue.

Inogen maintains a strong brand reputation as a market leader in portable oxygen concentrators. The company's reputation and commercial infrastructure are seen as assets that create leverage as it scales new product categories. The launch of Aurora CPAP masks and the Rove 6 portable oxygen concentrator demonstrate innovation and market expansion. Leadership appointments indicate strategic strengthening of the company's management. While Q1 2026 revenue exceeded expectations, the widening net loss due to increased investments could be perceived as a short-term challenge.

Inogen's ownership is primarily composed of institutional investors, holding approximately 70.39% as of May 2025, and around 73-74.82% as of July 2025 and April 2025 respectively. Major institutional shareholders include BlackRock, Inc. and Vanguard Group Inc. Individual insiders hold a smaller percentage of the stock, around 1.41% to 2.85%. Yuwell (Hong Kong) Holdings Limited made a substantial equity investment in February 2025, purchasing approximately 9.9% of outstanding common stock.